IMHO it was not a pumped milestone - the LymPro results were based on incomplete univariant data - specifically for the KOL's. The market was expecting full univariant results. Today's data completes that milestone fulfillment - were now on to multivariant test data results from here due no later than early Dec.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links